[1] The WHO Classification of Tumours Editorial Board. WHO Classification of Tumours of Soft Tissue and Bone[M]. Lyon:International Agency for Research on Cancer Press, 2020:303-305. [2] Meis-Kindblom JM, Bergh P, Gunterberg B, Kindblom LG. Extraskeletal myxoid chondrosarcoma:a reappraisal of its morphologic spectrum and prognostic factors based on 117 cases[J]. Am J Surg Pathol, 1999, 23:636-650. [3] Brown JM, Rakoczy K, Pretell-Mazzini J. Extraskeletal myxoid chondrosarcoma:clinical features and overall survival[J]. Cancer Treat Res Commun, 2022, 31:100530. [4] Paioli A, Stacchiotti S, Campanacci D, Palmerini E, Frezza AM, Longhi A, Radaelli S, Donati DM, Beltrami G, Bianchi G, Barisella M, Righi A, Benini S, Fiore M, Picci P, Gronchi A. Extraskeletal myxoid chondrosarcoma with molecularly confirmed diagnosis:a multicenter retrospective study within the Italian Sarcoma Group[J]. Ann Surg Oncol, 2021, 28:1142-1150. [5] Kapoor N, Shinagare AB, Jagannathan JP, Shah SH, Krajewski KM, Hornick JL, Ramaiya NH. Clinical and radiologic features of extraskeletal myxoid chondrosarcoma including initial presentation, local recurrence, and metastases[J]. Radiol Oncol, 2014, 48:235-242. [6] Hong YG, Yoo J, Kim SH, Chang JH. Intracranial extraskeletal myxoid chondrosarcoma in fourth ventricle[J]. Brain Tumor Res Treat, 2021, 9:75-80. [7] Velz J, Agaimy A, Frontzek K, Neidert MC, Bozinov O, Wagner U, Fritz C, Coras R, Hofer S, Bode-Lesniewska B, Rushing E. Molecular and clinicopathologic heterogeneity of intracranial tumors mimicking extraskeletal myxoid chondrosarcoma[J]. J Neuropathol Exp Neurol, 2018, 77:727-735. [8] Oliveira AM, Sebo TJ, McGrory JE, Gaffey TA, Rock MG, Nascimento AG. Extraskeletal myxoid chondrosarcoma:a clinicopathologic, immunohistochemical, and ploidy analysis of 23 cases[J]. Mod Pathol, 2000, 13:900-908. [9] Wang J, Zhu XZ. Pathology of soft tissue tumors[M]. 2nd ed. Beijing:People's Medical Publishing House, 2017:1206-1210.[王坚, 朱雄增.软组织肿瘤病理学[M]. 2版.北京:人民卫生出版社, 2017:1206-1210.] [10] Stacchiotti S, Baldi GG, Morosi C, Gronchi A, Maestro R. Extraskeletal myxoid chondrosarcoma:state of the art and current research on biology and clinical management[J]. Cancers (Basel), 2020, 12:2703. [11] Broehm CJ, Wu J, Gullapalli RR, Bocklage T. Extraskeletal myxoid chondrosarcoma with at (9;16)(q22;p11.2) resulting in a NR4A3-FUS fusion[J]. Cancer Genet, 2014, 207:276-280. [12] Agaram NP, Zhang L, Sung YS, Singer S, Antonescu CR. Extraskeletal myxoid chondrosarcoma with non-EWSR1-NR4A3 variant fusions correlate with rhabdoid phenotype and high-grade morphology[J]. Hum Pathol, 2014, 45:1084-1091. [13] Brenca M, Stacchiotti S, Fassetta K, Sbaraglia M, Janjusevic M, Racanelli D, Polano M, Rossi S, Brich S, Dagrada GP, Collini P, Colombo C, Gronchi A, Astolfi A, Indio V, Pantaleo MA, Picci P, Casali PG, Dei Tos AP, Pilotti S, Maestro R. NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas[J]. J Pathol, 2019, 249:90-101. [14] Wei S, Pei J, von Mehren M, Abraham JA, Patchefsky AS, Cooper HS. SMARCA2-NR4A3 is a novel fusion gene of extraskeletal myxoid chondrosarcoma identified by RNA next-generation sequencing[J]. Genes Chromosomes Cancer, 2021, 60:709-712. [15] Schaefer IM, Hornick JL. SWI/SNF complex-deficient soft tissue neoplasms:an update[J]. Semin Diagn Pathol, 2021, 38:222-231. [16] Kohashi K, Oda Y. Oncogenic roles of SMARCB1/INI1 and its deficient tumors[J]. Cancer Sci, 2017, 108:547-552. [17] Li L, Xia QY, Rao Q, Liu B, Wu B, Shi SS, Yu B, Zhang RS, Lu ZF, Zhou XJ. Molecular genetics and immunophenotype of INI1/SMARCB1 in epithelioid sarcoma[J]. Zhonghua Bing Li Xue Za Zhi, 2014, 43:389-393.[李莉, 夏秋媛, 饶秋, 刘标, 吴波, 时姗姗, 余波, 章如松, 陆珍凤, 周晓军.上皮样肉瘤免疫表型和INI1基因改变的研究[J].中华病理学杂志, 2014, 43:389-393.] [18] Jo VY, Fletcher CD. Epithelioid malignant peripheral nerve sheath tumor:clinicopathologic analysis of 63 cases[J]. Am J Surg Pathol, 2015, 39:673-682. [19] Li C, Zhang ZH, Pan MH, Fan QH. Malignant peripheral nerve sheath tumor:a clinicopathological study of 52 cases[J]. Lin Chuang Yu Shi Yan Bing Li Xue Za Zhi, 2016, 32:644-647.[李琛, 张智弘, 潘敏鸿, 范钦和.恶性外周神经鞘瘤52例临床病理分析[J].临床与实验病理学杂志, 2016, 32:644-647.] [20] Li Z. Introduction of newly identified tumor types in the 2021 WHO Classification of Tumors of the Central Nervous System (fifth edition)[J]. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2021, 21:769-782.[李智. 2021年世界卫生组织中枢神经系统肿瘤分类(第五版)新增肿瘤介绍[J].中国现代神经疾病杂志, 2021, 21:769-782.] [21] Yang XJ, Yin HF, Li Z, Yu SZ. Chinese version of simplified table of 2021 WHO Classification of Tumors of the Central Nervous System (fifth edition) and translational interpretations[J]. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2021, 21:746-750.[杨学军, 尹洪芳, 李智, 于士柱. 2021年世界卫生组织中枢神经系统肿瘤分类(第五版)简表中译版及说明[J].中国现代神经疾病杂志, 2021, 21:746-750.] [22] Thomas C, Wefers A, Bens S, Nemes K, Agaimy A, Oyen F, Vogelgesang S, Rodriguez FJ, Brett FM, McLendon R, Bodi I, Burel-Vandenbos F, Keyvani K, Tippelt S, Poulsen FR, Lipp ES, Giannini C, Reifenberger G, Kuchelmeister K, Pietsch T, Kordes U, Siebert R, Frühwald MC, Johann PD, Sill M, Kool M, von Deimling A, Paulus W, Hasselblatt M. Desmoplastic myxoid tumor, SMARCB1-mutant:clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults[J]. Acta Neuropathol, 2020, 139:277-286. [23] Li F, Shi Y, Yao XH, Feng H. Interpretation on circumscribed astrocytic gliomas in the 2021 WHO Classification of Tumors of the Central Nervous System (fifth edition)[J]. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2021, 21:804-808.[李飞, 时雨, 姚小红, 冯华. 2021年世界卫生组织中枢神经系统肿瘤分类(第五版)局限性星形细胞胶质瘤分类解读[J].中国现代神经疾病杂志, 2021, 21:804-808.] [24] Bielle F, Villa C, Giry M, Bergemer-Fouquet AM, Polivka M, Vasiljevic A, Aubriot-Lorton MH, Bernier M, Lechapt-Zalcman E, Viennet G, Sazdovitch V, Duyckaerts C, Sanson M, Figarella-Branger D, Mokhtari K; RENOP. Chordoid gliomas of the third ventricle share TTF-1 expression with organum vasculosum of the lamina terminalis[J]. Am J Surg Pathol, 2015, 39:948-956. |